These studies aim to investigate subcellular distribution of angiotensin II (Ang II) in rat luteal cells, identify other bioactive angiotensin peptides, and investigate a role for angiotensin peptides in luteal steroidogenesis. Confocal microscopy showed Ang II distributed within the cytoplasm, and nuclei of luteal cells. HPLC analysis showed peaks that eluted with the same retention times as Ang- Quinapril, ZPP, PCMS, PMSF, losartan, the angiotensin receptor type 1 (AT1), and PD123319, the AT2, receptor antagonists were used in progesterone production studies. ZPP significantly reduced LH-dependent progesterone production (p < 0.05). Quinapril plus ZPP had a greater inhibitory effect on LH-stimulated progesterone than either inhibitor alone, but this was not reversed by exogenous Ang II or Ang-(1-7). Both PCMS and PMSF acutely blocked LH-stimulated progesterone, and PCMS blocked LH-sensitive cyclic AMP accumulation.
INTRODUCTION
The formation of Ang II occurs as the result of a cascade reaction that is initiated by activation of prorenin to renin. The substrate angiotensinogen is hydrolyzed by renin, releasing the decapeptide, Ang I that in turn is substrate for angiotensin converting enzyme (ACE). ACE hydrolysis of Ang I results in the formation of the octapeptide Ang II, considered the major biologically active peptide of the cascade, and its proteolysis produces Ang III (Ang-(2-8)). Historically, Ang II was considered an adrenal hormone restricted to renal function, but evidence that Ang II is produced by other tissues, including the ovaries, began to emerge in the 1980's. The demonstration of ovarian angiotensinogen, Ang II receptors, and renin and ACE activity has been reviewed (52, 82) , and this ovarian renin angiotensin system (OVRAS) appears to be under gonadotrophin control. Prorenin/renin and Ang II/Ang III immunoreactivity is present in follicular fluid of women at significantly higher concentrations than in serum, indicating local ovarian synthesis (21, 39) , and these concentrations increase following gonadotrophin treatment, or during the mid-cycle gonadotrophin surge (39, 40, 63) .
Similarly in the rat, gonadotrophin regulation of the OVRAS is implicated since granulosa cells of immature developing follicles show no immunostaining for renin or Ang II, but at the time of the gonadotrophin surge, granulosa cells of the preovulatory follicle stain intensely for both these antigens (38) . However the role of the OVRAS in ovarian function remains to be clarified.
For example, Ang II mediates ovulation in the rat (50, 53) , but Ang II receptors in preovulatory follicles of this species have not been demonstrated (65) . Angiotensin II receptors are classified as type 1 (AT1) or type 2 (AT2) based on their pharmacology (11, 77) , and in the rat, the AT2 receptor is associated with atretic follicles (34) , suggesting a role in follicular atresia. On the other hand, in the rabbit, AT1 is present in granulosa cells and thecal cells of preovulatory follicles (18) , and in this species Ang II mediates meiotic maturation and stimulation of ovulation in part through prostaglandin production (35, 83) .
A role for Ang II in ovarian steroidogenesis also requires clarification. In vivo studies using a microdialysis system showed stimulatory effects of Ang II on progesterone output in the newly formed bovine corpus luteum (32) , but at late stages of luteal formation (day 15), Ang II has luteolytic effects (72) . In the case of bovine luteal cells in culture, Ang II inhibits cholesterol side-chain cleavage activity and reduces progesterone production (66) . Inhibitory effects of Ang II on LH-stimulated steroidogenesis also occur in cultured pig and human granulosa cells (28, 37) . In cultured rat luteal cells, we suggested that Ang II and the natural luteolysin PGF 2 could work together to reduce progesterone (79) , and more recently, a positive feedback loop between Ang II, endothelin, and PGF 2 , produced within the luteal environment, has been proposed to be key in functional and structural luteolysis of the bovine corpus luteum (72) .
Until recently, the renin-angiotensin system was considered to produce Ang II as the only biologically active molecule of the cascade. This view is challenged by the demonstration that additional biologically active angiotensin fragments are produced from angiotensinogen (reviewed in (13, 20) ). ACE hydrolysis of Ang I results in the formation of Ang II, that is further proteolytically degraded by aminopeptidase A to Ang III (Ang-(2-8)), or by aminopeptidase D to Ang IV (Ang-(3-8)), and other fragments (57) . An additional pathway for lysis of Ang I is via prolyl endopeptidase (EC 3.4.21.26) (PEP), or neutral endopeptidase (EC 3.4.24.11) (NEP) resulting in the formation of Ang-(1-7). However, Ang-(1-7) can also be directly formed from Ang II by PEP or prolyl carboxypeptidase activity. Thus, in addition to Ang II, other bioactive angiotensin peptides, including Ang III, Ang-(1-7), and Ang IV, can be produced by the renin-angiotensin cascade (20, 27) . Further biological complexity of the renin-angiotensin system is bestowed by specific angiotensin peptide receptors. The type 1 (AT1), and the type 2 (AT2) Ang II receptor, are recognized to mediate different actions (11, 78) , while receptors for Ang IV and Ang-(1-7) are also implicated since they often have opposing effects to those of Ang II (11, 16, 20, 43) , and recently the orphan receptor, Mas was proposed to be the Ang-(1-7) receptor (62) . Clearly, a combination of angiotensin peptides and their receptors in any given tissue can confer a highly complex regulatory system, and such complexity is indicated in the ovary (13) . It is the hypothesis of this study that since the corpus luteum is a source of Ang II (32, 48) , other angiotensin peptides are also produced, and that different angiotensin peptides may differentially regulate luteal steroidogenesis. Therefore, we intend to determine whether Ang-(1-7) is formed by the corpus luteum, and investigate the effects of angiotensin peptides on progesterone production.
METHODS

Animals
Immature (26-27 days old) female rats (CD strain, Charles River Laboratories, Wilmington, MA) were injected s.c. with 50 IU PMSG (Gestyl, Organon Pharmaceuticals, West Orange, NJ) to induce superovulation. Fifty four hours later, 25 IU human CG (hCG) (Wyeth-Ayerst Laboratories, Rouses Point, NY) was injected to induce ovulation and pseudopregnancy. All procedures were in accordance with institutional animal care and use committee guidelines.
Luteal cell isolation
Rat luteal cells were isolated by methods previously described (51) . Briefly, 5 days after injection of hCG, the ovaries were removed and finely minced with a razor blade. The ovarian fragments were suspended in 5 ml Ca 2+ -free Minimal Essential Medium (medium 1, 1380, GIBCO, Grand Island, NY) containing 0.1% bovine serum albumin (BSA, GIBCO), 2000 IU collagenase (Worthington Biochemical Corp., Freehold, NJ) and 3000 IU deoxyribonuclease (DNAase, Worthington) per g tissue, for 1 h at 37 o C under 95% air-5% CO2. The isolated luteal cells were enriched by density gradient sedimentation on a discontinuous density gradient (51) (Percoll, Pharmacia Fine Chemicals, Uppsala, Sweden). The cells were washed with 10 ml medium 1, collected by centrifugation and resuspended in Dulbecco's Modified Eagle's/Ham's F12 Medium at 0.5-1.0 million cells/ml containing 0.1% FCS, penicillin (100 U/ml), streptomycin (0.1 µg/ml), and amphotericin-B (0.25 µg/ml; all Gibco). Cell number was determined by means of hemocytometer, and cell viability was greater than 90 %, as assessed by exclusion of trypan blue dye.
Immunohistochemistry
Luteal cell suspensions in DMEM containing BSA (0.1%) were cultured in Lab-Tek culture slides for 24 hours, after which they were fixed with 4% paraformaldehyde in DPBS pH 7.4 for 1 hour.
Inhibition of endogenous luteal peroxidase was achieved with 5% hydrogen peroxide (1 hour). The cells were washed with DPBS, incubated with 0.1% triton-x in DPBS for 30 minutes at room temp, and then washed twice (5 min each) with DPBS. To recover antigenicity, cells were placed in a microwave oven for 1min at maximum power in citrate buffer (50 mM, pH6.0) (54), and then (54) washed once with DPBS for 5 minutes. Non-specific binding sites were blocked with Power Block TM (BioGenex, San Ramon, Ca) incubated at 37 o C for 20 minutes, followed by washing twice with DPBS for 5 min. The cells were incubated overnight at 4 o C with Ang II antibody (diluted 1:300 in DPBS containing BSA (3 %)) in a humidified, chamber. Before secondary labeling with streptavidin/DAB, the cells were washed in DPBS (1 x 5 min; 1 x 30 min, 1 x 10 min). The cells were then incubated with Multilink (BioGenex) for 10 min, washed three times (5 min each) in DPBS, followed by incubation with Label (BioGenex) for 15 min. Subsequently, cells were incubated with Substrate (BioGenex) for 5 minutes. The cells were counterstained with hematoxylin for 1 min, and NH 4 OH for 3 min, followed by a wash with deionized H 2 O before mounting.
In the case of confocal and fluorescence microscopy studies, paraformaldehyde fixed cells were incubated with triton-x 100 (0.1%) in DPBS for 30 min, and washed three times with DPBS (10 minutes each wash). Cells were incubated for 1h at 37 o C with DPBS containing 5% normal rabbit serum and 3% BSA (blocking solution), followed by three washes with DPBS (each 10 minutes).
Immunolabeling was achieved with rabbit anti-Ang-II antibody (1:400) in DPBS containing BSA (3%) incubated overnight at 4 o C, followed by 3 washes with DPBS (15 minutes each wash) and incubation for 45 minutes at room temp with fluorescein-labeled goat anti-rabbit IgG FAB (Cappel, Irvine, CA) (diluted 1:100 in blocking solution). Unbound label was removed by washing the cells three times with blocking solution, followed by two washes with DPBS alone. The slides were mounted with Slowfade (Molecular Probes, Portland, OR) containing propridium iodide.
HPLC Analysis
Angiotensin peptides were resolved by HPLC, based on published methods (9) . Isolated luteal cells were aliquotted to tubes, centrifuged (1200 x g, 10 minutes) and resuspended with intracellular 
Progesterone and cyclic AMP Radioimmunoassay
Total progesterone and cyclic AMP were determined in combined cells and media by specific radioimmunoassay, as previously described (51).
Angiotensin Converting Enzyme Activity
Angiotensin converting enzyme (ACE) activity was measured by means of o-aminobenzoylGly-p-Nitro-Phe-Pro (ABGP) which forms a fluorescent product upon cleavage by ACE ( 
Hormones, Drugs and Reagents
Ovine luteinizing hormone (oLH#26) was supplied by NIDDK. , Ang II and Ang III, but since we wished to investigate angiotensin processing pathways and effects of protease inhibitors, we incubated luteal cells with angiotensinogen as described in the Methods Section, to prevent substrate depletion effects that would compromise interpretation of the data. Figure 3 (B, lower panel) shows a luteal cell chromatogram with absorbance peaks that correlated with Ang-(1-7), Ang II and Ang III, and the relative amounts of these peptides were determined to be: Ang-(1-7), 586.5 ± 63.1 pmoles/mg; Ang II, 622.1 ± 87.2 pmoles/mg; and Ang III, 244.1 ± 55.9 pmoles/mg (n=8).
Protease inhibitors that may modulate angiotensin peptide include quinapril, a specific non-peptide, non-sulfhydryl, competitive inhibitor of ACE (12); PCMS, a sulfhydryl protease inhibitor;
ZPP, an inhibitor of PEP (61), and PMSF, a serine protease inhibitor. Luteal cells were incubated for 60 minutes in the presence of each inhibitor (100 µM) in DMEM containing BSA (0.1%), and then centrifuged and resuspended with IC buffer before a secondary incubation with protease inhibitor and angiotensinogen as described in the Methodology Section. Peptides were extracted, and subjected to HPLC. Table 1 Ang-(1-7), Ang II and Ang III, but no effect of PMSF on peptide accumulation was detected. Figure 4 summarizes data of studies that investigated the effects of protease inhibitors on basal and LH-stimulated steroidogenesis. Under basal conditions, quinapril and PMSF had no statistically significant effects; however PCMS at higher concentrations (100 µM) significantly reduced progesterone production (p < 0.05). ZPP on the other hand, enhanced progesterone output when compared to the effects of the other protease inhibitors, and at 100 µM the level of progesterone production was elevated compared to that of its control group (p< 0.05). In the case of LH-stimulated cells, the protease inhibitors tended to reduce progesterone production. PCMS and PMSF induced a dose-dependent inhibition that reached approximately 70 % and 50 % inhibition, respectively at the maximally tested concentration (100 µM). The effects of quinapril and ZPP were more subtle than those of PCMS and PMSF: ZPP (100 µM) inhibited LH-driven progesterone production approximately 15 % compared to the control group (p < 0.05); however, progesterone production in the presence of quinapril (100 µM) was not statistically different from control levels, although an approximate 10 % reduction in its output was detected when compared to cells incubated with 10 µM quinapril (p < 0.05).
Other protease inhibitors were tested at concentrations up to 100 µM and found to have no effect on basal or LH-stimulated progesterone production including benzamidine, pepstatin and aprotinin (data not shown).
The effects of the protease inhibitors on LH action may be mediated through the second messenger cyclic AMP (cAMP), therefore we investigated their effects on cAMP accumulation, and the results from these experiments are summarized in Figure 5 . Under basal conditions, no statistically significant dose-response effects were detected within the protease inhibitor treatments.
However among the treatment groups, cells treated with PCMS accumulated less cyclic AMP than did cells treated with quinapril, ZPP, or PMSF (p<0.05). LH-stimulated cAMP accumulation was also unaffected by quinapril, ZPP and PMSF, but in the presence of PCMS a dose-dependent inhibition occurred (p<0.05). We further investigated the regulatory effect of PCMS on LH-stimulated luteal cells and tested whether degradation of cAMP was enhanced in this treatment group. The phosphodiesterase inhibitor isobutyl methyl xanthine (IBMX) prevents cAMP hydrolysis, and the data of Figure 6 shows that LH-stimulated cAMP accumulation was enhanced (p<0.05) in the presence of IBMX (200 µM). However, IBMX did not block the inhibitory effect of PCMS on either cAMP accumulation, or progesterone production in LH-stimulated cells. In addition, the non-metabolized cAMP analog, dibutyryl (db) cAMP was tested, and PCMS also was inhibitory on dbcAMP-stimulated progesterone.
Transport of cholesterol to the mitochondria may be a target for protease inhibitors; therefore we used 22-OH-cholesterol that can enter mitochondria independently of LH-action and transporters.
We found that under these conditions the inhibitory effect of PMSF on progesterone production was reversed (Figure 7) , however, addition of 22OH-cholesterol only partially reversed the inhibitory effect of PCMS.
The protease inhibitors quinapril and ZPP target the proteases ACE and PEP that are enzymatic pathways for production of Ang II and Ang-(1-7), respectively. We investigated the effects of quinapril and ZPP on progesterone production and found that they had an additive inhibitory effect on LH-regulated progesterone production ( Figure 8) . However, addition of Ang II or Ang-(1-7) to cells incubated with quinapril and ZPP did not reverse their inhibitory effect. In contrast, 22OH-cholesterol did reverse the inhibition produced by quinapril and ZPP, and the levels of progesterone produced
were not significantly different from control cells ( Table 2 ).
The effects of exogenous Ang II and Ang-(1-7) on luteal steroidogenesis were also studied. In acute 1 hour incubations, no significant effect of Ang II or Ang-(1-7) on LH stimulated progesterone was found (Table 3) . Similarly, no effect of exogenous Ang I (3µM) on progesterone production was detected: LH = 9.9 ± 0.5 ng/10 5 cells; LH + Ang I = 9.4 ± 0.3 ng/10 5 cells, n = 4.
Expression of ACE activity in rat granulosa cells is linked to the LH-surge (38), and we wished to investigate whether LH-regulated ACE activity occurs in luteal cells. Luteal cells were incubated for 24 h with and without LH (100 ng/ml), washed, and further incubated for 3 h in the presence of ABGP (1 mM). Some incubations included quinapril (100 µM) to verify that the hydrolysis product was dependent on ACE activity. Luteal cells consistently hydrolyzed ABGP to a fluorescent product, and quinapril inhibited this activity. Furthermore, LH treatment of luteal cells resulted in an increase in fluorescence of ABGP product that was sensitive to quinapril ( Figure 9 ). LH consistently elevated ACE activity in 3 experiments tested, but the degree of stimulation showed some variability, ranging from 25% to 500 %.
Addition of extracellular Ang II had no significant effect on progesterone production, but protease inhibitors that can affect angiotensin processing were inhibitory on steroidogenesis. This data and the observed accumulation of cytoplasmic and nuclear Ang II suggest a potential intracellular regulatory site of action that may affect cell function. Therefore, we set out to modulate intracellular actions of angiotensin peptides by permeabilization of the luteal cell membrane with saponin and treatment with angiotensin peptides and receptor antagonists. . When permeabilized cells were incubated with losartan (1 µM), progesterone production was significantly reduced (p < 0.05), and this effect was reversed when Ang II (1 µM) was included with the antagonist. The type 2 Ang II receptor antagonist, PD123319 had no significant effect on progesterone production. In whole cells (non-permeabilized) losartan had no significant effect on progesterone production which was 97.7 ± 3.3 % compared to control incubations (100 %; mean ± SEM from four replicated experiments, p > 0.05).
DISCUSSION
Ang II can no longer be considered the only biologically active endpoint of the reninangiotensinogen cascade, as other angiotensin peptides have biological activity, including Ang III, Ang-(1-7) (3, 16) and Ang-(3-8) (27) . Ang III, Ang-(1-7) and Ang-(3-8) have some overlapping actions with Ang II due to partial occupancy of Ang II receptors, but importantly, Ang-(1-7) and Ang-(3-8) have their own receptors that mediate opposing actions to Ang II (27, 47) . In the present study, HPLC analysis of luteal cell incubations showed peaks that eluted with the same retention times as Ang II, Ang III and Ang-(1-7), and their relative quantities were: Ang II Ang-(1-7) >>Ang III.
These observations suggest that Ang II and Ang-(1-7) are significant products of angiotensinogen processing in the rat corpus luteum. The formation and regulation of Ang II and Ang-(1-7) in the ovary may have consequences for health and disease. Ang II and Ang-(1-7) are frequently counterregulatory: Ang II is a potent vasoconstrictor, stimulates mitogenesis, and has angiogenic effects, while
Ang-(1-7) is a vasodilator, reduces mitogenic activity, and opposes angiogenesis (5, 19, 33, 41, 69) .
Thus, the balance of production of these two peptides may play a role in formation of the corpus luteum, and also play a role in ovarian pathologies such as ovarian cancer, thereby underlining the importance to understand their biochemical pathways.
PCMS, the sulfhydryl protease inhibitor significantly inhibited accumulation of Ang-(1-7), Ang II and Ang III. The broad inhibitory effects of PCMS on angiotensins are likely due to the sulfhydryl groups of ACE that are susceptible to PCMS (14, 23) , thereby inhibiting hydrolysis of Ang I to Ang II, that can be precursor for both Ang-(1-7) and Ang III. In addition, a sulfhydryl containing peptidase identified in a neuroblastoma-glioma cell line (8) may also occur in luteal cells, and contribute to PCMS-sensitive inhibited Ang-(1-7) accumulation. The serine protease inhibitor PMSF was without effect on accumulation of angiotensin peptides. In some tissues PMSF inhibits activation of prorenin to renin, and also reduces Ang II accumulation (60, 70) , but the present data does not identify a role for serine protease activity in angiotensinogen processing in luteal cells. The broad specificity of PCMS and PMSF directed studies with quinapril and ZPP that represent more specific inhibitors of proteases of angiotensin processing. Quinapril specifically inhibits ACE mediated hydrolysis of Ang I to Ang II (12) , and ZPP inhibits the PEP pathway that hydrolyses Ang I or Ang II to Ang-(1-7) (8, 61).
Treatment of luteal cells with quinapril significantly reduced accumulation of Ang III, but a trend of reduced accumulation of Ang II did not reach statistical significance. These findings suggest that the proteolytic cascade of Ang I to Ang II to Ang III via ACE activity is not a major pathway in luteal cells. Alternative angiotensinogen processing that can give rise to Ang II production includes direct proteolysis of angiotensinogen to Ang II, independent of renin and ACE activity (20) ; in addition chymase/cathespsin G appears the major enzyme that converts Ang I to Ang II in heart tissue (29). It is not clear whether a similar pathway may occur in luteal cells since chymase/cathespsin G is a serine protease, and in our studies we found no significant effect of the serine protease inhibitor PMSF on accumulation of Ang II. Further studies are necessary to identify whether pathways, in addition to ACE, generate Ang II from Ang I in the rat corpus luteum. However, alternative ovarian pathways of Ang II formation could explain the lack of effect of competitive ACE inhibitors on ovulation observed in studies with rats and rabbits (15, 59) , species known to be dependent on Ang II for ovulation (50, 84) . 1-7) was unaffected by ZPP by itself, we cannot rule out that reduced levels of production coupled with a low turnover maintains Ang-(1-7) levels in luteal cells. In addition, Ang-(1-7) production directly from Ang I via NEP that is independent of Ang II and ACE activity can occur in some cell types (61) , and a similar route in luteal tissues may contribute to accumulated Ang- (1-7) levels. The effect of alternative pathways of angiotensinogen processing includes the result that shutting down one pathway can drive enhanced accumulation of other angiotensin peptides. It is conceivable that in vivo, different pathways may operate in specific conditions of health or disease.
Indeed, levels of circulating Ang-(1-7) and Ang II increase during pregnancy in the human, and a change in the ratio of their concentration is implicated in the onset of pre-eclampsia (45) , but it remains to be determined whether the imbalance in their ratios arises from differential angiotensin peptide production by the corpus luteum of pregnancy.
The effects of the protease inhibitors on basal steroidogenesis correlated with their effects on Ang II accumulation. Quinapril and PMSF had no significant effects on progesterone production or Ang II accumulation; PCMS at higher concentrations inhibited progesterone and Ang II levels; while ZPP enhanced basal progesterone production and Ang II accumulation. These effects of protease inhibitors on basal progesterone production may be unrelated to angiotensin processing, and due to effects on the steroidogenic machinery. However, other studies have investigated ACE inhibition and ovarian steroidogenesis, and reported various effects. Inhibition of ACE activity in the frog ovary enhanced estradiol and progesterone production (4); in a hyperstimulated rabbit model, progesterone was unaffected and estradiol production was decreased (59); and in PMSG-treated rats, ACE inhibition by captopril infusion reduced serum levels of progesterone and enhanced estradiol output (2) .
The varying physiologic responses to ACE inhibition may be due to alternative angiotensinogen processing pathways in different species, but a further complicating factor is likely to be gonadotrophin treatment. Previous studies identified an interaction between LH and the OVRAS.
LH stimulates bovine thecal cell production and secretion of renin/prorenin through a cyclic AMPdependent mechanism (6), and in vivo, gonadotrophin stimulation leads to enhanced ovarian Ang II levels in the bovine and human (1, 39) . Whether this effect is a direct response to gonadotrophin or a secondary event is unclear. Bovine luteal ACE has been located to the endothelial cell population, and its activity is upregulated by a combination of estradiol and vascular endothelial growth factor (VEGF), but not estradiol alone (25, 33) . However, the testicular ACE isoform (ACE T ) is regulated by gonadotrophins by a cAMP response element on the ACE gene (30, 75) . We found an LH-dependent increase in ACE activity in cultured rat luteal cells that may be mediated by the LH second messenger cAMP. It is possible that enhanced ACE activity occurred in a population of endothelial cells as a secondary event to LH-stimulated endocrine cells. However, the luteal cells are purified by densitygradient sedimentation, and are principally steroidogenic cells (73) , suggesting a direct effect of LH on luteal ACE. The hypothesis of LH-regulated luteal ACE activity is also supported by a report that inhibition of ACE in women during normal menstrual cycles is without effect on serum steroid levels, but in gonadotrophin-stimulated women during the luteal phase of IVF cycles, ACE inhibition reduces serum levels of progesterone and elevates estradiol (46) . In our studies, progesterone output was unaffected by quinapril under basal conditions, but in LH-stimulated cells, an inhibitory effect was indicated when quinapril was included with ZPP. Taken together, inhibition of ACE activity may principally have steroidogenic effects in gonadotrophin-stimulated cells, but it remains to be determined whether enhanced ACE activity and corresponding Ang II production play a role in LHstimulated steroidogenesis.
LH-stimulated progesterone production was also inhibited by ZPP, PCMS and PMSF. PCMS and PMSF had the most profound inhibitory effects on progesterone production, but only PCMS affected accumulation of Ang II and Ang-(1-7). We did not test the effect of exogenous Ang II or Ang-(1-7) with PCMS, but these peptides had no significant effect on progesterone production when added by themselves. The actions of PCMS and PMSF may be related to cholesterol transport (see below), and further studies are required to identify if their anti-steroidogenic sites of action include angiotensin processing.
Ang-(1-7) stimulates progesterone output in perfused rat ovaries from gonadotrophin primed animals (13), but we found no effect of exogenous Ang II or Ang-(1-7) on progesterone production in luteal cells. Furthermore, ZPP that inhibits PEP, a mediator of Ang-(1-7) production, had differential effects on progesterone that related to gonadotrophin stimulation, since basal progesterone was enhanced and LH-stimulated progesterone was inhibited by ZPP. These different responses may be specific for tissue, or due to hormonal pre-treatment. We do not know whether LH regulates Ang-(1-7) accumulation, but luteal ACE activity was enhanced by LH, and since Ang-(1-7) production may occur via ACE and PEP activity, elevated Ang II may drive elevated Ang-(1-7) production. We found that quinapril plus ZPP reduced accumulation of Ang-(1-7), while a trend of reduced Ang II and Ang III accumulation did not reach statistical significance. In LH-stimulated cells, quinapril plus ZPP significantly reduced progesterone production to a greater extent than did either quinapril or ZPP alone, but this effect was not reversed by exogenous Ang II or Ang-(1-7). It is possible that the inhibitory action of quinapril plus ZPP are due to direct effects on the steroidogenic machinery, or alternatively, intracellular angiotensin processing may modulate steroidogenesis. In support of this latter hypothesis, intracellular generation of Ang II, and intracellular effects mediated by nuclear and cytosolic Ang II binding sites have been described in different cell types (17, 24, 26, 31, 71) . Indeed in the present studies, immunofluorescence and confocal microscopy shows intracellular accumulation of Ang II within cytoplasm and nuclei. Therefore, we tested the effects of agonists and antagonists in permeabilized luteal cells that allow penetration of extracellular molecules to the intracellular milieu.
In this paradigm neither Ang II, nor Ang-(1-7) significantly affected progesterone compared to control levels, although luteal cells incubated with Ang II produced significantly more progesterone than did cells incubated with Ang-(1-7). Furthermore, progesterone production was significantly reduced by losartan, and this effect was reversed when Ang II was included with the receptor antagonist. The AT2 antagonist, PD123319 had no effect on steroidogenesis in intact or permeabilized cells. These data suggest that intracellular levels of Ang II can modulate steroidogenesis via AT1 receptors.
Investigation of the mechanism of action of the protease inhibitors included adenylate cyclase activity that mediates LH-stimulation of steroidogenesis. Quinapril, ZPP and PMSF did not affect cAMP levels in either basal or LH-stimulated paradigms, but in contrast, PCMS did inhibit LHstimulated cAMP accumulation. This effect was not due to enhanced degradation of cAMP by phosphodiesterase activity, because the phosphodiesterase inhibitor, IBMX did not reverse PCMSinduced effects. We cannot rule out that a protease-dependent requirement for LH binding to its receptor (22) is a factor, or that PCMS may have a direct effect on adenylate cyclase activity (42).
However, PCMS also exerted effects on steroidogenesis at a site post-adenylate cyclase because dbcAMP-stimulated progesterone was blocked by PCMS. Basal progesterone was largely unaffected by PMSF and PCMS, except for a high concentration of PCMS, but a more pronounced inhibition of progesterone production occurred in LH-stimulated cells that could be related to cholesterol transport.
Investigation of the post-adenylate cyclase site of action utilized 22OH-cholesterol that permeates mitochondria independently of transport mechanisms. PMSF-dependent inhibition of steroidogenesis was fully reversed, while PCMS-dependent inhibition was mostly restored by 22OH-cholesterol.
Therefore, PMSF and PCMS may affect cholesterol transport to the mitochondria and/or P450scc at sites including: sterol carrier protein 2 (SCP 2 ) that regulates cholesterol transport from the lipid droplet to the mitochondria; steroidogenesis activator polypeptide; and steroid acute regulatory peptide (StAR) (49, 68, 74) . However, SCP 2 is slowly turned over (58), and therefore seems unlikely to be effected by the acute treatment in the present studies. On the other hand, StAR is rapidly synthesized in response to LH and cAMP, and is a key protein for transport of cholesterol from the outer to the inner mitochondrial membrane where the P450scc resides (10, 56) . During its import to the inner membrane, StAR is proteolytically degraded from a 37 kDa precursor to a 30 kDa protein (55, 67) and may be sensitive to PCMS and PMSF. Indeed, in adrenal, and Leydig cells, PMSF blocks stimulated steroidogenesis, at least in part, by inhibition of turnover of the 37 kDa StAR precursor (44) . It is unknown, whether quinapril or ZPP affect the 37 kDa StAR precursor but their combined inhibitory effect was reversed by 20OH-cholesterol, suggesting an inhibitory site of action before P450scc.
Better understanding of the complexity of the OVRAS may allow new diagnostic and treatment strategies. In beginning to examine such complexities, we conclude from these studies that angiotensin Table 2 Progesterone production by rat luteal cells that were preincubated with ZPP plus quinapril (100 µM each) for 60 minutes, then subsequently incubated with 22OH-cholesterol ( 20 µg/ml) and LH (100 ng/ml) for 60 minutes. Data are the mean + SEM, n=4. 
Control
